Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B-Containing Lipoprotein and HDL in Type 2 Diabetes: A potential mechanism to lower plasma triglycerides

G. M. Dallinga-Thie, I. I.L. Berk-Planken, A. H. Bootsma, H. Jansen
2004 Diabetes Care  
OBJECTIVE -Apolipoprotein (apo)C-III is a constituent of HDL (HDL apoC-III) and of apoB-containing lipoproteins (LpB:C-III). It slows the clearance of triglyceride-rich lipoproteins (TRLs) by inhibition of the activity of the enzyme lipoprotein lipase (LPL) and by interference with lipoprotein binding to cell-surface receptors. Elevated plasma LpB:C-III is an independent risk factor for cardiovascular disease. We studied the effect of atorvastatin on plasma LpB:C-III and HDL apoC-III. RESEARCH
more » ... ESIGN AND METHODS - We studied the effect of 30 weeks' treatment with 10 and 80 mg atorvastatin on plasma apoC-III levels in a randomized, double-blind, placebo-controlled trial involving 217 patients with type 2 diabetes and fasting plasma triglycerides between 1.5 and 6.0 mmol/l. RESULTS -Baseline levels of total plasma apoC-III, HDL apoC-III, and LpB:C-III were 41.5 Ϯ 10.0, 17.7 Ϯ 5.5, and 23.8 Ϯ 7.7 mg/l, respectively. Plasma apoC-III was strongly correlated with plasma triglycerides (r ϭ 0.74, P Ͻ 0.001). Atorvastatin 10-and 80-mg treatment significantly decreased plasma apoC-III (atorvastatin 10 mg, 21%, and 80 mg, 27%), HDL apoC-III (atorvastatin 10 mg, 22%, and 80 mg, 28%) and LpB:C-III (atorvastatin 10 mg, 23%, and 80 mg, 28%; all P Ͻ 0.001). The decrease in plasma apoC-III, mainly in LpB:C-III, strongly correlated with a decrease in triglycerides (atorvastatin 10 mg, r ϭ 0.70, and 80 mg, r ϭ 0.78; P Ͻ 0.001). Atorvastatin treatment also leads to a reduction in the HDL apoC-III-to-HDL cholesterol and HDL apoC-III-to-apoA-I ratios, indicating a change in the number of apoC-III per HDL particle (atorvastatin 10 mg, Ϫ21%, and 80 mg, Ϫ31%; P Ͻ 0.001). CONCLUSIONS -Atorvastatin treatment resulted in a significant dose-dependent reduction in plasma apoC-III, HDL apoC-III, and LpB:C-III levels in patients with type 2 diabetes. These data indicate a potentially important antiatherogenic effect of statin treatment and may explain (part of) the triglyceride-lowering effect of atorvastatin.
doi:10.2337/diacare.27.6.1358 pmid:15161788 fatcat:myamfdhxazcjpov4lpy2n2uzaa